By Ronald S. Litman
In January 2020, the Anesthetic and Analgesic Drug Products Advisory Committee of the FDA (AADPAC) met jointly with the Drug Safety and Risk Management Advisory Committee (DSaRM) to consider approval of three opioid-related new drug applications (NDAs).